Core Viewpoint - The company has achieved significant milestones with its drug development and stock market performance, indicating strong investor interest and potential growth opportunities. Group 1: Drug Development - The company announced that its oral PD-L1 inhibitor ABSK043 and the KRAS G12C inhibitor from Elysium, Goretinib, received IND approval in China for a Phase II clinical trial targeting KRAS G12C mutated NSCLC [1] - In March, the company entered into a collaboration agreement with Elysium regarding ABSK043, which is now being evaluated in combination with Goretinib [1] Group 2: Stock Market Performance - The company's stock opened over 6% higher, reaching a historical high of 18.92 HKD, and is currently trading at 18.28 HKD with a trading volume of 11.2474 million HKD [1] - On August 13, the company was included in the MSCI Global Small Cap Index, effective after the market close on August 26 [1] - Allianz SE increased its stake in the company from 4.81% to 5.10%, joining other notable foreign investors such as Eli Lilly Asia, Qiming Venture Partners, and Morgan Stanley [1] - The company repurchased 200,000 shares on August 27 and another 100,000 shares on August 28, totaling 9.545 million shares repurchased for 75.3 million HKD as of June 30, 2025 [1]

Core Viewpoint - The company, He Yu-B (02256), has experienced a significant stock price increase following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with Elysium's KRAS G12C inhibitor for treating KRAS G12C mutated NSCLC [1] Group 1: Clinical Developments - The IND application for the combination therapy of ABSK043 and Elysium's KRAS G12C inhibitor has been approved in China [1] - The approval pertains to a Phase II clinical trial evaluating the efficacy of the combination treatment for KRAS G12C mutated NSCLC [1] Group 2: Market Performance - The stock opened over 6% higher, reaching a historical high of 18.92 HKD, and is currently trading at 18.5 HKD with a trading volume of 56,300 HKD [1] - The company has been included in the MSCI Global Small Cap Index as of August 26, following the latest index review [1] Group 3: Shareholder Activity - Allianz SE has increased its stake in the company from 4.81% to 5.10% [1] - The company has conducted share buybacks, repurchasing 200,000 shares on August 27 and another 100,000 shares on August 28, totaling 9.545 million shares repurchased for 75.3 million HKD as of June 30, 2025 [1]

Core Viewpoint - The company, He Yu-B (02256), has seen a significant increase in stock price following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with ELI LILLY's KRAS G12C inhibitor for treating KRAS G12C mutated NSCLC [1] Group 1: Stock Performance - He Yu-B's stock opened over 6% higher, reaching a historical high of 18.92 HKD, and is currently trading at 18.5 HKD with a trading volume of 56,300 HKD [1] - The stock has experienced a 3.87% increase as of the latest report [1] Group 2: Clinical Development - The IND application for the combination treatment of ABSK043 and ELI LILLY's KRAS G12C inhibitor for KRAS G12C mutated NSCLC has been approved in China [1] - The approval pertains to a Phase II clinical trial for the combination therapy [1] Group 3: Index Inclusion and Shareholder Activity - He Yu-B has been included in the MSCI Global Small Cap Index as of August 26, following the latest index review [1] - Allianz SE has increased its stake in He Yu-B from 4.81% to 5.10%, joining other notable foreign investors such as Eli Lilly Asia, Qiming Venture Partners, and Morgan Stanley [1] - The company has repurchased a total of 9.545 million shares, amounting to 75.3 million HKD, with recent buybacks of 200,000 shares on August 27 and 100,000 shares on August 28 [1]